The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

SARS-CoV-2 Variants

Since emerging in 2019, SARS-CoV-2’s genome has proved to be relatively stable. However, the emergence of multiple new variants in late 2020 has caused concern over the efficacy of recently-developed countermeasures, including diagnostics, therapeutics and vaccines. Many mutations have occurred in the Spike protein and its receptor-binding domain (RBD), which plays a central role in pathogenesis and the induction of neutralising antibodies. To identify and investigate the effects of these mutations, extensive work is now underway. Click here to see our full coronavirus range.

Our Spike Mutants

To support the investigation of SARS-CoV-2 variants, The Native Antigen Company offers a growing range of mutant Spike antigens. Expressed from our proprietary mammalian expression system, these antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications. For more information on our available products, click the green text in the far-right column below:

 

Mutant Spike Trimer
SARS-CoV-2 Dominant Lineage
Spike Mutations
Antigen
Availability
&npsb;
Omicron Variant (BA.5)
&npsb;
&npsb;
G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC32036 >>>
&npsb;
Omicron Variant (B.1.1.529)
&npsb;
A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC32008 >>>
&npsb;
Omicron Variant (B.1.1.529)
&npsb;
G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC32007 >>>
&npsb;
Omicron Variant (B.1.1.529)
&npsb;
A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y
&npsb;
Spike S1 Subunit
&npsb;
REC32006 >>>
&npsb;
Wuhan-Hu-1 Wild-Type
&npsb;
&npsb;
N/A
&npsb;
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31966 >>>
&npsb;
Wuhan-Hu-1 Wild-Type
&npsb;
&npsb;
N/A
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31882 >>>
&npsb;
Alpha Variant (B.1.1.7)
&npsb;
69-70del, Y144del, N501Y, A570D, P681H, T716I, S982A, D1118H
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31924 >>>
&npsb;
Alpha Variant (B.1.1.7)
&npsb;
N501Y
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31946 >>>
&npsb;
Beta Variant (B.351.1/501Y.V2)
&npsb;
&npsb;
L18F, D80A, D215G, del242-244, K417N, E484K, N501Y, D614G, A701V
&npsb;
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31963 >>>
&npsb;
Beta Variant (B.1.351/501Y.V2)
&npsb;
&npsb;
D80A, D215G, K417N, E484K, N501Y, A701V
&npsb;
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31926 >>>
&npsb;
Beta Variant (B.1.351/501Y.V2)
&npsb;
&npsb;
K417N, E484K, N501Y
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31945 >>>
&npsb;
Delta Variant (B.1.617.2)
&npsb;
&npsb;
T19R, T95I, G142D, E156G, del157-158, W258L, N417K, L452R, T478K, D614G, P681R, D950N
&npsb;
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31975 >>>
&npsb;
Delta Variant (B.1.617.2)
&npsb;
&npsb;
L452R, T478K
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31974 >>>
&npsb;
Gamma Variant (B.1.1.28)
&npsb;
&npsb;
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
&npsb;
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31944 >>>
&npsb;
Gamma Variant (B.1.1.28)
&npsb;
&npsb;
K417T, E484K, N501Y
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31961 >>>
&npsb;
Kappa Variant (B.1.617.1)
&npsb;
&npsb;
E484Q, L452R
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31971 >>>
&npsb;
Lambda Variant (C.37)
&npsb;
&npsb;
G75V, T76I, 246-252del, L452Q, F490S, D614G, T859N
&npsb;
&npsb;
Pre-Fusion Stabilised Whole Spike
&npsb;
REC31976 >>>
&npsb;
Lambda Variant (C.37)
&npsb;
&npsb;
L452Q, F490S
&npsb;
&npsb;
Spike Receptor-Binding Domain
&npsb;
REC31992 >>>

Custom Services

The Native Antigen Company also offers services to develop custom variants via site-directed mutagenesis, including the ablation of specific glycans. For multiple, or more substantial mutations such as indels, we are able to develop antigens de novo. For the investigation of mutant binding, we also offer recombinant ACE2 proteins and services to raise monoclonal and polyclonal antibodies with mutant antigens. To get in touch with a member of our R&D team, click the button below:

Spike Mutation Map

The map below shows all the Spike mutations we currently provide or are developing in relation to the original Wuhan-Hu-1 sequence:

SARS-CoV-2 Variant Mutation Map

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

13 + 8 =

Live Customer Feedback